Company / SG&A Expense
Veracyte, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$110.8M
FY2025
5-year range
$73.2M / $110.8M
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
#128 of 152
Health Care
What the data says
Veracyte, Inc.'s sg&a expense of $111M is lower than 84% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $73M in FY2022 to $111M in FY2025.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of +24.7%.
Increased from $86M to $111M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +24.7%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 152This company $110.8M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +24.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 0.2% year-over-year.
- Ranks #128 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.8M | +0.2% |
| FY2024 | $110.6M | +28.3% |
| FY2023 | $86.2M | +17.8% |
| FY2022 | $73.2M | -27.8% |
| FY2021 | $101.4M | +175.9% |
| FY2020 | $36.7M | +26.5% |
| FY2019 | $29.0M | +21.1% |
| FY2018 | $24.0M | +3.8% |
| FY2017 | $23.1M | -2.9% |
| FY2016 | $23.8M | +5.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026